VV-HiPLO
Viral Vector High-Performance Line Optimizer

A computational framework for designing and evaluating high-yield viral vector production systems through promoter engineering, helper-plasmid architecture optimization, codon optimization, and manufacturing economics modeling.

Project Vision

One of the largest challenges in gene therapy manufacturing is the low productivity of viral vector production systems.

Current AAV and lentiviral manufacturing processes often suffer from:

Low vector yields
High manufacturing costs
Limited scalability
Complex upstream processing
Expensive commercial production

VV-HiPLO was developed to explore whether computational optimization techniques can identify promoter architectures and helper plasmid designs that may significantly improve viral vector production efficiency.

Objective

Develop a computational pipeline capable of:

Ranking viral promoters
Designing helper plasmid architectures
Evaluating codon optimization strategies
Predicting relative production yields
Modeling manufacturing economics
Prioritizing candidate designs for laboratory testing
Computational Workflow
Stage 1 — Promoter Analysis

The framework evaluates promoter candidates using:

GC content analysis
Transcription factor density estimation
Promoter architecture scoring
Composite strength ranking

Promoters analyzed include:

CMV
CAG
SFFV
PGK
EF1α
UBC
Custom synthetic designs
Stage 2 — Sequence Optimization

Coding sequences are evaluated using:

Codon Adaptation Index (CAI)
GC balance
Host-cell compatibility scoring
Sequence complexity metrics

Target host:

HEK293-derived production systems
Stage 3 — Helper Plasmid Architecture Design

Multiple helper-plasmid configurations were modeled including:

Dual-expression systems
Tri-cassette systems
Inducible architectures
Stoichiometric balancing designs
Insulated expression cassettes

Each design was scored using:

Promoter strength
Expression balance
Regulatory element support
Architecture complexity
Manufacturing feasibility
Stage 4 — Yield Prediction Engine

The framework combines multiple biological and engineering features:

Promoter performance
Codon optimization metrics
Stoichiometry models
Regulatory element contributions
Transfection efficiency factors
Packaging constraints

to generate relative yield predictions and candidate rankings.

Stage 5 — Manufacturing Economics

The pipeline estimates:

Relative manufacturing cost reduction
Production scalability
Potential profitability improvements
Cost-per-gram projections
Key Computational Findings
Top Candidate

HiPLO-Insulated-Premium

Predicted characteristics:

Optimized promoter architecture
Multi-layer insulation strategy
Regulatory element stacking
Codon-optimized expression cassettes
Predicted Performance
Metric	Result
Predicted Yield	779,054 vg/cell
Predicted Improvement	10.4×
Estimated Cost Reduction	~10×
Predicted Cost per Gram	~$24K
Baseline Cost per Gram	~$250K
Feature Importance Analysis

Major contributors to predicted performance:

Insulation strategy
Serotype factor
Codon optimization
Packaging size optimization
Promoter strength
GC-content optimization
Transfection efficiency
Stoichiometric balance
Generated Outputs

The framework produces:

Promoter rankings
Yield prediction dashboards
Architecture visualizations
Cost analyses
Serotype comparisons
Candidate sequence reports
Scientific Significance

This project demonstrates how computational biology, synthetic biology, and machine learning can be integrated to prioritize viral vector manufacturing strategies before costly laboratory experimentation.

Potential applications include:

AAV manufacturing optimization
Lentiviral manufacturing optimization
Producer cell line engineering
Synthetic promoter discovery
Bioprocess development
Current Status
Computational Validation Complete

The framework successfully identified candidate designs predicted to improve manufacturing performance.

Experimental Validation Required

All results in this repository are computational predictions.

Laboratory validation is required before any scientific, commercial, or clinical conclusions can be drawn.

Recommended validation methods include:

Triple-transfection assays
qPCR vector genome quantification
Capsid ELISA
Transduction assays
Bioreactor scale-up studies
Disclaimer

This repository contains computational analyses and predictive models intended for research and educational purposes.

The reported yields, fold-improvements, and economic projections are model-generated estimates and should not be interpreted as experimentally verified biological performance.

Future Development

Planned upgrades include:

Multi-objective optimization
Deep learning sequence models
Reinforcement learning architecture search
Large-scale promoter discovery
Automated Design-Build-Test-Learn workflows
Integration with experimental datasets
Citation

If you use this work in research or development projects, please cite:

VV-HiPLO: Viral Vector High-Performance Line Optimizer
Computational Framework for Viral Vector Manufacturing Optimization
2026 | Dr Agnish Reddy
